Clinical Trial

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 26, 2024 (before its estimated June 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase II, prospective, randomized, open label, controlled, multi-center study, aim to evaluate the activity of Tislelizumab and Anlotinib and chemotherapy compared with Tislelizumab and chemotherapy before surgery, followed by Tislelizumab alone as adjuvant therapy. The primary objective of this study is to evaluate and compare pathological complete response rate(pCR).
Trial Details
NCT Number NCT06475755
Lead Sponsor Tang-Du Hospital
Conditions Non-Small Cell Lung Cancer, Anti Angiogenesis
Enrollment 178 participants
Start Date 2024-06-30
Primary Completion 2025-06-10 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-06-26